World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
30224
World Ranking
14022
National Ranking
461

H. Miles Prince publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where H. Miles Prince sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 547 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

H. Miles Prince D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where H. Miles Prince sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

H. Miles Prince is affiliated with the Peter MacCallum Cancer Centre in Australia. Their primary field of research lies within Medicine with a significant focus on Pathology and Forensic Medicine, Oncology, Hematology, Dermatology, and Molecular Biology.

Their research covers a broad range of topics including:

  • Lymphoma Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments
  • Cutaneous lymphoproliferative disorders research
  • CAR-T cell therapy research
  • Protein Degradation and Inhibitors
  • T-cell and Retrovirus Studies
  • Monoclonal and Polyclonal Antibodies Research

Their frequently collaborating coauthors include:

  • Carrie van der Weyden (30 coauthored works)
  • Hang Quach (24 coauthored works)
  • Belinda A. Campbell (23 coauthored works)
  • Philippe Moreau (16 coauthored works)
  • Julia Scarisbrick (15 coauthored works)

H. Miles Prince has published extensively in recognized venues. The most common publication journals include:

  • Blood (31 publications)
  • Clinical Lymphoma Myeloma & Leukemia (12 publications)
  • Internal Medicine Journal (8 publications)
  • Journal of Clinical Oncology (8 publications)
  • Leukemia & lymphoma/Leukemia and lymphoma (8 publications)

Several recent representative papers authored or coauthored by H. Miles Prince are as follows:

  • "Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results" (2023) published in Nature Medicine
  • "Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC" (2021) published in Blood
  • "Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data" (2021) published in Blood Advances
  • "T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma" (2020) published in Blood Advances
  • "Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study" (2020) published in British Journal of Dermatology

Best Publications

  • Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Meletios Dimopoulos;Andrew Spencer;Michael Attal;H. Miles Prince

  • Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

    Richard L. Piekarz;Robin Frye;Maria Turner;John J. Wright

  • Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

    Elise A. Olsen;Sean Whittaker;Youn H. Kim;Madeleine Duvic

  • Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

    Bertrand Coiffier;Barbara Pro;H. Miles Prince;Francine Foss

  • Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

    H Quach;D Ritchie;D Ritchie;A K Stewart;P Neeson

  • Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Michel Attal;Paul G. Richardson;S. Vincent Rajkumar;Jesus San-Miguel

  • Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    H Miles Prince;H Miles Prince;Youn H Kim;Steven M Horwitz;Reinhard Dummer

  • Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

    Richard L. Piekarz;Robin Frye;H. Miles Prince;Mark H. Kirschbaum

  • Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

    David S. Ritchie;Paul J. Neeson;Paul J. Neeson;Amit Khot;Stefan Peinert

  • EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

    Werner Kempf;Katrin Pfaltz;Maarten H. Vermeer;Antonio Cozzio

  • Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure

    Andrew Spencer;H. Miles Prince;Andrew W. Roberts;Ian W. Prosser

  • Clinical studies of histone deacetylase inhibitors.

    H Miles Prince;Mark J Bishton;Simon J Harrison

  • Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients

    Roberto N. Miranda;Tariq N. Aladily;H. Miles Prince;Rashmi Kanagal-Shamanna

  • Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

    Julia J. Scarisbrick;H. Miles Prince;Maarten H. Vermeer;Pietro Quaglino

  • A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease

    Mary E D Flowers;Jane F. Apperley;Koen Van Besien;Ahmet Elmaagacli

  • Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk

    Anna Loch-Wilkinson;Kenneth J. Beath;Robert John William Knight;William Louis Fick Wessels

  • Bacterial Biofilm Infection Detected in Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

    Honghua Hu;Khalid Johani;Ahmad Almatroudi;Karen Vickery

  • Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

    Leigh Ellis;Yan Pan;Gordon K. Smyth;Daniel J. George

  • Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

    Anas Younes;Anna Sureda;Dina Ben-Yehuda;Pier Luigi Zinzani

  • Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia

    Brian J P Huntly;Alistair G Reid;Anthony J Bench;L J Campbell

Frequent Co-Authors

John F. Seymour
John F. Seymour Peter MacCallum Cancer Centre
David Ritchie
David Ritchie Peter MacCallum Cancer Centre
Ricky W. Johnstone
Ricky W. Johnstone Peter MacCallum Cancer Centre
Constantine S. Tam
Constantine S. Tam University of Melbourne
Madeleine Duvic
Madeleine Duvic The University of Texas MD Anderson Cancer Center
Andrew Spencer
Andrew Spencer Monash University
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Michael H. Kershaw
Michael H. Kershaw Peter MacCallum Cancer Centre
Sean Whittaker
Sean Whittaker King's College London
Phillip K. Darcy
Phillip K. Darcy Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are interested in exploring additional healthcare careers or enhancing your credentials, a variety of related online programs can help you get started. For those seeking leadership roles, online health administration programs can provide the skills needed to manage healthcare organizations effectively and grow in the rapidly evolving medical field.

Nurses aspiring to advance can benefit from bridge programs such as rn to np, which allow registered nurses to become nurse practitioners and take on more specialized roles in patient care. Similarly, those with a passion for nutrition and wellness can consider an online dietitian degree, preparing them for roles in hospitals, clinics, or public health settings.

For those aiming for high-level administrative positions, pursuing top cahme-accredited mha programs ensures a reputable and comprehensive education in healthcare management. These flexible online pathways make it possible for working professionals and students to continue their education and broaden their career opportunities within medicine and beyond.

Best Scientists Citing H. Miles Prince

Trending Scientists

Recently Published Articles